Idiopathic pulmonary fibrosis: current concepts
- PMID: 9818046
- DOI: 10.4065/73.11.1085
Idiopathic pulmonary fibrosis: current concepts
Abstract
Idiopathic pulmonary fibrosis (IPF) is generally defined as a progressive, fibrosing inflammatory disease of the lung parenchyma of unknown cause. It is characterized by slowly increasing dyspnea, diffuse interstitial lung infiltrates, restrictive lung dysfunction, and impaired gas exchange. Ultimately, it is fatal in most patients, and treatment options remain unsatisfactory. The advent of high-resolution computed tomography of the chest and modifications in the histopathologic classification of interstitial pneumonias have reshaped the concept of IPF. Although initially thought to be a relatively specific clinicopathologic entity, it seems likely that IPF as previously defined is a heterogeneous disorder consisting of several clinicopathologic entities with differing histopathologic patterns, clinical course, response to therapy, and prognosis. The most common histologic pattern in cases previously defined as IPF is usual interstitial pneumonia, which is associated with a median survival of less than 3 years. For accurate prognosis and optimal management of patients, the clinician should attempt to be as precise as possible in distinguishing various clinicopathologic entities that have been included under the clinical heading of IPF. In the future, we recommend that the use of the term "idiopathic pulmonary fibrosis" be restricted to patients with usual interstitial pneumonia and that clinicians recognize the fact that other idiopathic interstitial pneumonias do not have the same prognostic effect traditionally ascribed to IPF.
Comment in
-
Ahead to the past.Mayo Clin Proc. 1999 May;74(5):533-4. doi: 10.4065/74.5.533-d. Mayo Clin Proc. 1999. PMID: 10319091 No abstract available.
Similar articles
-
Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis.Clin Exp Med. 2003 Sep;3(2):65-83. doi: 10.1007/s10238-003-0010-3. Clin Exp Med. 2003. PMID: 14598183 Review.
-
[Idiopathic pulmonary fibrosis].Vnitr Lek. 2005 Dec;51(12):1375-84. Vnitr Lek. 2005. PMID: 16430105 Review. Czech.
-
Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis.Clin Chest Med. 2006 Mar;27(1 Suppl 1):S17-25, v-vi. doi: 10.1016/j.ccm.2005.08.001. Clin Chest Med. 2006. PMID: 16545629 Review.
-
[Idiopathic diffuse interstitial lung disease].Rev Prat. 2000 Nov 1;50(17):1901-5. Rev Prat. 2000. PMID: 11151331 Review. French.
-
Spectrum of fibrosing diffuse parenchymal lung disease.Mt Sinai J Med. 2009 Feb;76(1):2-23. doi: 10.1002/msj.20087. Mt Sinai J Med. 2009. PMID: 19170214 Review.
Cited by
-
Role of Sensory Nerves in Pulmonary Fibrosis.Int J Mol Sci. 2024 Mar 21;25(6):3538. doi: 10.3390/ijms25063538. Int J Mol Sci. 2024. PMID: 38542511 Free PMC article. Review.
-
Role of Mesenchymal Stem Cells and Extracellular Vesicles in Idiopathic Pulmonary Fibrosis.Int J Mol Sci. 2022 Sep 23;23(19):11212. doi: 10.3390/ijms231911212. Int J Mol Sci. 2022. PMID: 36232511 Free PMC article. Review.
-
Danggui Buxue Tang Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Suppressing the TLR4/NLRP3 Signaling Pathway in Rats.Evid Based Complement Alternat Med. 2021 Jul 23;2021:8030143. doi: 10.1155/2021/8030143. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34349830 Free PMC article.
-
Fibroblasts from patients with idiopathic pulmonary fibrosis are resistant to cisplatin-induced cell death via enhanced CK2-dependent XRCC1 activity.Apoptosis. 2019 Jun;24(5-6):499-510. doi: 10.1007/s10495-019-01529-9. Apoptosis. 2019. PMID: 30850922 Free PMC article.
-
Silencing of heart and neural crest derivatives expressed transcript 2 attenuates transforming growth factor-β1-enhanced apoptosis of human bronchial epithelial cells.Oncol Lett. 2018 Oct;16(4):4997-5005. doi: 10.3892/ol.2018.9299. Epub 2018 Aug 13. Oncol Lett. 2018. PMID: 30250565 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
